Hilton Miami Airport
5101 Blue Lagoon Dr
Miami, FL 33126

Registration Fee
There is no registration fee for this activity.

Special Accommodations

NACE fully complies with the legal requirements of the Americans with Disabilities Act. Any activity registrant who feels s/he may need accommodations based on the impact of a disability should contact NACE to discuss your specific need.

Event Parking
A discounted self-parking rate of $8.00 is available at the hotel.

Program Summary

Primary care providers face complex challenges everyday in their busy practices. With rapid changes in medicine, staying informed about new developments can be equally challenging. Our goal in this CME activity is to help you hone your skills in the diagnosis and management of patients with varied conditions you are likely encountering in your practice.

We have recruited a faculty of well-known thought leaders and experienced teachers who, as clinicians themselves, understand the challenges you face every day as a primary care provider. Our faculty will be at your disposal to provide evidence-based science, current treatment guidelines, discuss challenging cases, and provide answers for you that can ultimately lead to better health care for your patients. The presentations will include several interactive cases and discussion sessions to keep you actively learning.

Please join us and become an active participant in this one-day learning community of your peers.

Learning Objectives

At the conclusion of this program, participants should be able to:

1. Review the pathophysiology of atherosclerotic cardiovascular disease (ASCVD) and congestive heart failure (CHF) in T2DM; Recognize how the mechanism of action of the SGLT-2 inhibitor class can potentially have a beneficial impact on cardio-renal disease; Discuss CVOTs to date in T2DM and the impact of the SGLT-2 inhibitor class on improving cardiovascular outcomes and preventing progression of chronic kidney disease (CKD); Incorporate evolving clinical data into the management of diabetes in patients with, or at high risk for, cardiovascular disease (CVD).
2. Describe nocturia’s impact on affected patients; Evaluate symptoms of nocturia in affected patients in order to determine the source of symptoms; Assess current pharmacologic and non-pharmacologic nocturia management strategies; Differentiate the mechanisms of action, and safety and efficacy profiles of available and emerging therapies for nocturia.
3. Identify patients at high risk for osteoporotic fractures; Use validated tools to individualize risk assessment of bone health; Individualize therapy based on patient need and the characteristics of available pharmacologic agents; Apply various modalities to improve adherence to treatment plans.
4. Assess the clinical impact of herpes zoster and postherpetic neuralgia; Evaluate the efficacy, tolerability, and safety of available vaccines to prevent herpes zoster; Develop effective strategies to promote adherence to national vaccine guidelines.
5. Explain and apply CDC and other guidelines for initiating treatment for influenza in specific patient populations; Assess new and emerging antiviral therapies profiles used to treat influenza; Demonstrate effective communication techniques to address perceptions of symptom severity, vaccination measures, and therapeutic safety and efficacy.

Agenda*
7:30-8:00 am
Continental Breakfast and Registration

8:00-8:10
Welcome Remarks – Deborah Paschal CRNP, AC-AGNP

8:10-9:20
Individualizing Diabetes Care-The Impact of CV Risk on Therapeutic Strategy
Javier Morales, MD, FACP, FACE

9:20-10:30
Identification, Evaluation, and Treatment of Nocturia in the Primary Care Setting in 2019
David R. Staskin, MD

10:30-10:50
Break

10:50-12:00 pm
Metabolic Bone Disease and Optimization of Fracture Prevention
Javier Morales, MD, FACP, FACE

12:00-1:10
Lunch

1:10-2:20
Addressing Unmet Needs in Herpes Zoster: Sharing Strategies to Improve Care
Donald B. Middleton, MD

2:20-3:30
What’s New with the Flu?
Paul G. Auwaerter, MD

3:30-3:45
Summary of Key Points and Closing Remarks – Deborah Paschal CRNP, AC-AGNP

* Agenda subject to change

Faculty
Paul G. Auwaerter, MD
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD

Donald B. Middleton, MD
Professor of Family Medicine
UPMC St. Margaret
University of Pittsburgh School of Medicine
Pittsburgh, PA

Javier Morales, MD, FACP, FACE
Clinical Associate Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell University
Vice President
Advanced Internal Medicine Group, P.C.
East Hills, NY

David R. Staskin, MD
Associate Professor of Urology
Tufts University School of Medicine
Director, Center for Male and Female Pelvic Health
St. Elizabeth’s Medical Center
Boston, MA

Moderator
Deborah Paschal, CRNP
Clinical Nurse Practitioner
Philadelphia, PA

Planning Committee
Gregg Sherman, MD
Chief Medical Officer/Course Director
National Association for Continuing Education
Plantation, FL

Daniela Hiedra
Activity Director
National Association for Continuing Education
Plantation, FL

Sandy Bihlmeyer, M.Ed.
Senior Project Manager
National Association for Continuing Education
Plantation, FL

Michelle Frisch, MPH, CHCP
Vice President of Operations
National Association for Continuing Education
Plantation, FL

Joshua F. Kilbridge
President and Creative Director
Kilbridge Associates
San Francisco, CA

Deborah Paschal, CRNP
Clinical Nurse Practitioner
Philadelphia, PA

Sponsored and Certified By
National Association for Continuing Education

Accreditation  Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
The National Association for Continuing Education designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NACE AANP Approval
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 6.0 Contact hour(s) of continuing education, which includes 3.0 pharmacology hours.

Addressing Unmet Needs in Herpes Zoster: Sharing Strategies to Improve Care

Sponsored and Certified By
Albert Einstein College of Medicine

Accreditation Statement
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Albert Einstein College of Medicine designates this live activity for a maximum of 1.25AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosure Statement
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. All planners are also required to disclose all relevant financial relationships. Disclosure information will be provided in the activity materials.

Commercial Support Disclosure
This educational activity is supported by an educational grant from Genentech, an educational grant from GlaxoSmithKline, and an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC. This activity has been funded by an educational grant from Ferring Pharmaceuticals, Inc.